In today’s briefing:
- EQD | Commonwealth Bank (CBA AU) – Expected Move on Profit Announcement and Option Insights
- Uranium Wild Predictions and which Base Metals Restart will Make Bank First?
- CSL Ltd (CSL AU): Weak Vaccine Sales Affect H1FY25 Performance; FY25 Guidance Maintained
EQD | Commonwealth Bank (CBA AU) – Expected Move on Profit Announcement and Option Insights
- Commonwealth Bank of Australia (CBA AU) is set to announce its 2025 Half Year Results on 12 February.
- Option prices suggest a 2.4% move in either direction, which is less than the historic move of 3.4% over the past six announcements.
- Traders can trade the event through 13 February 2025 listed options (weekly expiration).
Uranium Wild Predictions and which Base Metals Restart will Make Bank First?
- BHP plans for a small increase in uranium production at Olympic Dam, with speculation on the impact
- Interview with Grant Isaac from Cameco sheds light on the uranium market trends
This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.
CSL Ltd (CSL AU): Weak Vaccine Sales Affect H1FY25 Performance; FY25 Guidance Maintained
- For H1FY25, CSL Ltd (CSL AU) reported net profit of $2.01B, up 6% YoY, missing estimate of $2.07B. Underlying profit (NPATA) grew 3% YoY to $2.07B.
- H1FY25 revenue increased 5% YoY to $8.48B. Solid performance from CSL Behring and CSL Vifor was partially offset by negative impact from CSL Seqirus.
- The company has reaffirmed FY25 underlying profit guidance of $3.2–3.3B at constant currency, up 10–13% YoY. Revenue growth is anticipated to be 5–7% YoY at constant currency.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
